Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call

25 Mar 2024
www.biospace.com
Financial Statement
Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ET NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Company plans to hold its first investor earnings call to discuss the results contained in its FY 2023 Form 10K, which it plans to day, and its outlook for FY 2024. The Company plans to hold its earnings call, open to the public, at 4:30 pm ET on Monday, April 1st, to discuss the results of its Q4 and FY 2023, which it plans to publish in its Form 10K to be filed with the SEC that day. On the call, management also plans to discuss the company's outlook for FY 2024, including expectations for additional data readouts from the ongoing PT00114 clinical trial. Participants in the discussion about the outlook for the trial will be Robert B. Stein, MD, PhD, Chief Medical Officer, and Andrew Slee, PhD, Chief Operating Officer, as well as Garo H. Armen, PhD, Executive Chairman. The log-in link is: . For those wishing to participate by phone only, dial: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 628544 About Protagenic Therapeutics, Inc.: Protagenic Therapeutics, Inc. (Nasdaq: PTIX) is committed to pioneering neuro-active peptides into therapeutics to mitigate stress-related disorders. For more information, visit . About PT00114: PT00114, a 41-amino-acid residue synthetic peptide, holds promise as a novel treatment for serious neuro-psychiatric conditions, including depression, anxiety, and PTSD. It is a synthetic form of the naturally-occurring brain peptide TCAP, which acts to counter the negative biochemical and behavioral effects of the stress-induced brain hormones Corticotropin Releasing Factor and Arginine-Vasopressin. Among the beneficial effects of PT00114 is the reduction of excessive circulating levels of cortisol that often are part of the response to various stressors. Forward-Looking Statements: This press release contains forward-looking statements concerning Protagenic Therapeutics' product candidates and clinical trial plans. These statements are subject to various risks and uncertainties. Investors are urged to exercise caution and not place undue reliance on these forward-looking statements. Company Contact: Alexander K. Arrow, MD, CFA Chief Financial Officer Protagenic Therapeutics, Inc. 149 Fifth Ave, Suite 500, New York, NY 10010. Tel: 213-260-4342 Email: alex.arrow@protagenic.com Investor Relations Contact: Kirin M. Smith, President, PCG Advisory, Inc. 950 Third Avenue, Suite #2700, New York, NY 10022. Tel: 646-823-8656 Email: ksmith@pcgadvisory.com SOURCE: Protagenic Therapeutics, Inc. View the original press release on accesswire.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.